Chan Ye Xin Xi Wang·2025-08-27 01:21Overview - The monoclonal antibody (mAb) market in China is still in its early stages, with many overseas mAbs not yet approved domestically. The high cost of these drugs limits accessibility for many patients with lower payment capabilities. However, the market penetration of mAbs is gradually increasing due to their significant advantages over traditional drugs, updates to the national medical insurance catalog, and rising national income levels. The market size of China's mAb industry is projected to reach 131.5 billion yuan in 2024, representing a year-on-year growth of 30.85% [1][5]. Industry Chain - The upstream of the mAb industry includes suppliers of raw materials such as cell culture media, enzymes, antibodies, reagents, consumables, and packaging materials, as well as core equipment suppliers like bioreactors and purification devices. The midstream consists of mAb research and production companies, while the downstream includes hospitals, DTP pharmacies, retail pharmacies, and online channels. Hospitals are the most critical distribution channel for mAbs in China, especially for drugs listed in the medical insurance catalog [3][5]. Development Background - The application of mAbs in cancer treatment is widespread, with the number of new cancer cases in China projected to reach 5.064 million in 2024, a year-on-year increase of 2.61%. This growing cancer population drives the demand for mAbs. Additionally, mAbs have shown efficacy in treating other diseases, such as asthma and inflammatory bowel diseases, providing new development opportunities for the mAb industry [4][5]. Current Status - Since the launch of the first therapeutic mAb in 1986, the mAb market has rapidly developed, with significant products like trastuzumab and adalimumab emerging. By 2024, the global mAb market size is expected to reach 273.3 billion USD, with a year-on-year growth of 9.15% [4][5]. Competitive Landscape - In the global pharmaceutical market, mAbs are becoming a cornerstone of biopharmaceuticals, with 8 mAbs appearing in the top 20 global drug sales rankings in 2024. The success of mAbs in treating tumors and immune diseases is notable, and advancements in biopharmaceutical technology may expand their role in treating infectious diseases [5][6]. Domestic Market Dynamics - In 2024, only 7 mAbs are among the top 30 chemical and biological drugs sold in Chinese hospitals, indicating significant room for growth in the domestic mAb market. The market is expected to expand further as domestic companies gain market share [7][8]. Company Analysis - Domestic companies like BeiGene, Innovent Biologics, Junshi Biosciences, and others are increasingly capturing market share previously dominated by multinational corporations. For instance, BeiGene's Tislelizumab leads in the PD-1 mAb market in China, while Innovent's Sintilimab and Junshi's Toripalimab also hold significant positions [8][9]. Future Trends - The quality and efficacy of domestic mAbs are expected to improve with ongoing advancements in research and production technologies. This may lead to a further increase in market share, breaking the monopoly of multinational companies. Additionally, the application of mAbs is anticipated to expand beyond cancer and autoimmune diseases to include infectious and transmissible diseases [11].